Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for na ïve patients with intermediate or poor risk prognosis (International mRCC Database Consortium). The efficacy of subsequent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after nivolumab-ipilimumab failure remains unclear.

Source: European Journal of Cancer - January 5, 2019 Category: Cancer & Oncology Authors: Marie Auvray, Edouard Auclin, Philippe Barthelemy, Petri Bono, Pirkko Kellokumpu-Lehtinen, Marine Gross-Goupil, Guillermo De Velasco, Thomas Powles, Guillaume Mouillet, Yann-Alexandre Vano, Gwena ëlle Gravis, Loïc Mourey, Franck Priou, Frédéric Rollan Tags: Original Research Source Type: research